Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 05 Feb 2013 New trial record
- 26 Jan 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.